Henlius

Innovating high-quality, affordable treatments to improve lives worldwide.

[Henlius @HenliusBiotech]

HER2-targeted therapy remains key to improving outcomes in HER2-positive gastric cancer. In a recent interview, Dr. Lin Shen discusses the rationale behind HLX22, a novel epitopeanti-HER2 monoclonal antibody designed to complement trastuzumab through a differentiated mechanism.

[Henlius @HenliusBiotech]

We’re excited to share that the first U.S. patient has been dosed in the global multicenter Phase 1 study of #HLX17, our self-developed #pembrolizumab biosimilar, for adjuvant treatment across multiple resected solid tumors.
🔗: https://t.co/yEXdHNV4qH

[Henlius @HenliusBiotech]

From June 22–25, Henlius will be at #BIO International Convention 2026 in San Diego Convention Center (Booth #5841), showcasing our latest innovation platforms and pipeline advancements, as well as our progress in global development.

Look forward to seeing you in San Diego!

[Henlius @HenliusBiotech]

Phase 3 results of anti-PD-1 monoclonal antibody #serplulimab in the perioperative treatment of resectable gastric cancer, were presented in an Oral Abstract Session at #ASCO 2026 and simultaneously published in @TheLancet.
🔗: https://t.co/tyekAk5CvF

[Henlius @HenliusBiotech]

At ASCO 2026, Henlius presented updated clinical data for our investigational PD-L1 ADC, #HLX43, in non-small cell lung cancer (NSCLC) through a Rapid Oral Abstract Session, including the first disclosure of progression-free survival (PFS) data.
🔗: https://t.co/O4mTgOQyOc

[Henlius @HenliusBiotech]

This World No Tobacco Day, let’s choose healthier lungs and a healthier future.
Behind every breath is a chance for life, hope, and healing. By saying no to tobacco, we take one step closer to reducing the burden of cancer and protecting the people we love.
#WorldNoTobaccoDay

[Henlius @HenliusBiotech]

Trilled to announce that our self-developed pertuzumab biosimilar HLX11 (trade name: POHERDY® in US and Europe) has been approved in China for HER2-positive breast cancer.
🔗: https://t.co/YQuonJl2Po

[Henlius @HenliusBiotech]

We are pleased to announce that the global Phase 2/3 trial of our PD-L1 ADC #HLX43 in previously treated sqNSCLC has completed First Patient Dosed in China, with recent PMDA clearance in Japan, further advancing its global development.
🔗: https://t.co/BEGlZ5fClK

[Henlius @HenliusBiotech]

We recently spoke with @YJanjigianMD — U.S. Principal Investigator of the HLX22-GC-301 trial, about the evolving HER2 treatment paradigm, the scientific rationale behind HLX22, and the potential of dual HER2 blockade in the first-line setting.
📹Watch full interview below.

[Henlius @HenliusBiotech]

We are pleased to announce that the first patient has been dosed in China in the MRCT Phase 1 trial of our self-developed subcutaneous #daratumumab biosimilar candidate, HLX15-SC, for the first-line treatment of newly diagnosed multiple myeloma (NDMM).
🔗: https://t.co/zbrSD0NJDP

[Henlius @HenliusBiotech]

Excited to share that our PD-L1 ADC HLX43 will present its full NSCLC dataset at ASCO, selected for a Rapid Oral Presentation on May 30. The presentation will feature the first subgroup PFS data.
🔗: https://t.co/jv1TXSdTvk

[Henlius @HenliusBiotech]

We are pleased to announce that the MRCT Phase II/III study of our anti-EGFR mAb pimurutamab (HLX07) in combination with anti-PD-1 mAb serplulimab and chemotherapy as first-line treatment for advanced sqNSCLC has completed first patient dosed in China.
🔗:https://t.co/aBsPL5sTmi

[Henlius @HenliusBiotech]

Thrilled to share that our independently developed anti-PD-1 mAb serplulimab has received a positive CHMP opinion for use in combination with chemotherapy as a first-line treatment for unresectable locally advanced or metastatic #sqNSCLC.
🔗: https://t.co/oOZRW90RyI

[Henlius @HenliusBiotech]

Our potential first-in-class (FIC) #B7H3-targeting sialidase fusion protein #HLX316 has completed First Patient Dosed (FPD) in its Phase 1 trial in advanced or metastatic solid tumors in China, marking its entry into clinical development.
🔗: https://t.co/hAggJ7RLkx

[Henlius @HenliusBiotech]

Thrilled to share that our anti-PD-1 mAb #serplulimab will present 8 studies at #ASCO 2026 across gastric/GEJ adenocarcinoma, colorectal cancer and head & neck squamous cell carcinoma, highlighting its expanding clinical potential in solid tumors.
🔗: https://t.co/YOTiHTAQDf

[Henlius @HenliusBiotech]

We’re pleased to announce that our STEAP1×CD3×CD28 trispecific T cell engager (#TCE) has received clinical trial approval in Australia for the treatment of metastatic castration-resistant prostate cancer (#mCRPC) and other advanced solid tumors.
🔗: https://t.co/FFxY4syVCL

[Henlius @HenliusBiotech]

We’re pleased to share that the first EU patient has been dosed in Spain in the global Phase 2 study of our PD-L1 ADC #HLX43 for advanced #NSCLC. Further accelerating the global clinical development of HLX43.
🔗: https://t.co/6NMjAgVwKE

[Henlius @HenliusBiotech]

We’re excited to announce that #HLX48, our self-developed #EGFR/#cMet bispecific #ADC, has received IND approval from China’s NMPA for the treatment of advanced/metastatic solid tumors.
🔗: https://t.co/L3rcPBv7a2

[Henlius @HenliusBiotech]

Recently, we interviewed @JafferAjaniMD from MD Anderson Cancer Center, Global PI of the HLX22-GC-301 trial. Encouraging Phase 2 data with 39-month follow-up further supports confidence in HLX22.

🎥 Watch the full interview below.

[Henlius @HenliusBiotech]

At #ESTRO 2026, held in Stockholm, Sweden from May 15–19, Phase 2 study results of #serplulimab in combination with chemoradiotherapy as neoadjuvant treatment for MSS/pMMR locally advanced colon cancer (#LACC) were presented in an oral session.
🔗: https://t.co/D0exIOrS4O